Drug Profile
Research programme: antibody-coupled T-cell receptor therapeutics - Cogent Biosciences/Seagen
Alternative Names: Antibody-coupled T cell receptor + anti-GPC3 antibodyLatest Information Update: 13 Oct 2020
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Developer Cogent Biosciences
- Class Antibodies; Antineoplastics; Recombinant fusion proteins; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 08 Oct 2020 Seattle Genetics is now called Seagen
- 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences
- 28 Jun 2020 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)